Skip to main content
Clinical Trials/NCT04579562
NCT04579562
Unknown
Not Applicable

Regional Epidemiology of COVID-19 and Acute Kidney Injury in England

University Hospitals of Derby and Burton NHS Foundation Trust0 sites5,000 target enrollmentNovember 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Kidney Injury
Sponsor
University Hospitals of Derby and Burton NHS Foundation Trust
Enrollment
5000
Primary Endpoint
acute kidney injury
Last Updated
5 years ago

Overview

Brief Summary

The COVID-19 pandemic has exposed the unwanted variation in outcomes as evidence by Public Health England's report on increased mortality in regions of the country. For example, UHDB, in East Midlands, has reported a high crude mortality as compared to other Trusts in the region.8 There may also have been variation in the incidence of complications of COVID-19 in the form of AKI, which may have influenced mortality. Variation in outcomes may be because of various factors - differing population demographics, underlying health conditions in the population, deprivation, physician preference and knowledge and ethnic diversity. Unwanted variation is care that is not consistent with a patient's preference or related to [their] underlying illness. It is important to understand the reason for unwanted variation in outcomes associated with COVID-19 to minimise patient harm and reduce morbidity and mortality.

Registry
clinicaltrials.gov
Start Date
November 1, 2020
End Date
October 31, 2021
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • This study will have two work packages (WP). Work Package 1 (WP1): Regional epidemiology of COVID-19 in England All patients who are admitted to hospital with COVID-19 infection between 1st March 2020 and 30th June 2020 and who meet following criteria will be included
  • Diagnostic code for COVID-19 (U07.1) in any of the 20 diagnoses codes
  • Adult patients greater or equal to 18 years of age.
  • Work Package 2 (WP2): Epidemiology of COVID-19 associated AKI in England All patients who are admitted to hospital with acute kidney injury (AKI) between 1st March 2020 and 30th June 2020 and who meet following criteria will be included
  • Diagnostic code for AKI (N17) in any of the 20 diagnoses codes
  • Adult patients greater or equal to 18 years of age.

Exclusion Criteria

  • The following patients will be excluded from the study
  • Patients not admitted to the hospital
  • Paediatric patients \< 18 years of age
  • The following patients will be excluded from the study
  • Patients not admitted to the hospital
  • Paediatric patients \< 18 years of age
  • Patients on chronic maintenance haemodialysis or peritoneal dialysis

Outcomes

Primary Outcomes

acute kidney injury

Time Frame: 30 days

Incidence of acute kidney injury in patients with COVID-19

All-cause mortality

Time Frame: 30 days

In-hospital all cause mortality in patients with acute kidney injury and COVID-19

Secondary Outcomes

  • Mechanical ventilation(30 days)

Similar Trials